Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Dacarbazine and Interferon Alfa-2b for High-Risk Uveal Melanoma
NCT01100528Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2009
- Primary completion
- Jul 2015
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacarbazine and interferon alfa-2b in Uveal melanoma (UM), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Disease-free Survival at 5 years. Started Nov 2009; status: completed.
02
Drugs
dacarbazineinterferon alfa-2b
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01100528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01100528.